143 related articles for article (PubMed ID: 20193452)
1. [Comments on American Society of Clinical Oncology/College of American Pathologists for HER2 testing in breast cancer].
Gong Y; Xiao CH; Fu L
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):795-8. PubMed ID: 20193452
[No Abstract] [Full Text] [Related]
2. A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria.
Schalper KA; Kumar S; Hui P; Rimm DL; Gershkovich P
Arch Pathol Lab Med; 2014 Feb; 138(2):213-9. PubMed ID: 24164555
[TBL] [Abstract][Full Text] [Related]
3. New ASCO/CAP guideline recommendations for HER2 testing increase the proportion of reflex in situ hybridization tests and of HER2 positive breast cancers.
Tchrakian N; Flanagan L; Harford J; Gannon JM; Quinn CM
Virchows Arch; 2016 Feb; 468(2):207-11. PubMed ID: 26521061
[TBL] [Abstract][Full Text] [Related]
4. Laboratory compliance with the American Society of Clinical Oncology/College of American Pathologists human epidermal growth factor receptor 2 testing guidelines: a 3-year comparison of validation procedures.
Dyhdalo KS; Fitzgibbons PL; Goldsmith JD; Souers RJ; Nakhleh RE
Arch Pathol Lab Med; 2014 Jul; 138(7):876-84. PubMed ID: 24978913
[TBL] [Abstract][Full Text] [Related]
5. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
[TBL] [Abstract][Full Text] [Related]
6. [Guidelines for HER2 detection in breast cancer, the 2009 version].
Guideline Recommendations for HER2 Detection in Breast Cancer Group
Zhonghua Bing Li Xue Za Zhi; 2009 Dec; 38(12):836-40. PubMed ID: 20193462
[No Abstract] [Full Text] [Related]
7. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
[TBL] [Abstract][Full Text] [Related]
8. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
9. ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia.
Farshid G; Bilous M; Morey A; Fox S; Lakhani S; Loi S; Bell R; Spillane A
Pathology; 2019 Jun; 51(4):345-348. PubMed ID: 31076089
[TBL] [Abstract][Full Text] [Related]
10. Current HER2 Testing Recommendations and Clinical Relevance as a Predictor of Response to Targeted Therapy.
Ballinger TJ; Sanders ME; Abramson VG
Clin Breast Cancer; 2015 Jun; 15(3):171-80. PubMed ID: 25516402
[TBL] [Abstract][Full Text] [Related]
11. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
[TBL] [Abstract][Full Text] [Related]
12. Impact of the Updated 2018 American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Li A; Bai Q; Kong H; Zhou S; Lv H; Zhong S; Li M; Bi R; Zhou X; Yang W
Arch Pathol Lab Med; 2020 Sep; 144(9):1097-1107. PubMed ID: 32142367
[TBL] [Abstract][Full Text] [Related]
13. HER2 testing: current status and future directions.
Perez EA; Cortés J; Gonzalez-Angulo AM; Bartlett JM
Cancer Treat Rev; 2014 Mar; 40(2):276-84. PubMed ID: 24080154
[TBL] [Abstract][Full Text] [Related]
14. The updated ASCO/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice.
Rakha EA; Starczynski J; Lee AH; Ellis IO
Histopathology; 2014 Apr; 64(5):609-15. PubMed ID: 24382093
[TBL] [Abstract][Full Text] [Related]
15. American Society of Clinical Oncology/College of American Pathologists 2018 Focused Update of Breast Cancer HER2 FISH Testing GuidelinesResults From a National Reference Laboratory.
Lin L; Sirohi D; Coleman JF; Gulbahce HE
Am J Clin Pathol; 2019 Sep; 152(4):479-485. PubMed ID: 31172196
[TBL] [Abstract][Full Text] [Related]
16. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
Lim SJ; Cantillep A; Carpenter PM
Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
[TBL] [Abstract][Full Text] [Related]
17. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
[TBL] [Abstract][Full Text] [Related]
18. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
[TBL] [Abstract][Full Text] [Related]
19. Clinical and health economic outcomes of alternative HER2 test strategies for guiding adjuvant trastuzumab therapy.
Lee JA; Shaheen M; Walke T; Daly M
Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):325-41. PubMed ID: 21671702
[TBL] [Abstract][Full Text] [Related]
20. Bright-field HER2 dual in situ hybridization (DISH) assay vs fluorescence in situ hybridization (FISH): focused study of immunohistochemical 2+ cases.
Gao FF; Dabbs DJ; Cooper KL; Bhargava R
Am J Clin Pathol; 2014 Jan; 141(1):102-10. PubMed ID: 24343743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
